Evaluation of Dopamine Transporter Density in Healthy Brazilians Using [99mTc] TRODAT-1 SPECT

Marilia Alves dos Reis  
Universidade Federal de Sao Paulo

Ary Gadelha  
Universidade Federal de Sao Paulo: Universidade Federal de Sao Paulo

André C. Felício  
Hospital Israelita Albert Einstein

Marcelo Queiroz Hoexter  
Universidade Federal de Sao Paulo: Universidade Federal de Sao Paulo

Ilza Rosa Batista  
Universidade Federal de Sao Paulo: Universidade Federal de Sao Paulo

Pedro Braga-Neto  
Universidade Federal do Ceará

Mariana Calzavara  
Universidade Federal de Sao Paulo: Universidade Federal de Sao Paulo

Daniel Alves Cavagnolli  
Universidade Federal de Sao Paulo: Universidade Federal de Sao Paulo

Cinthia Higuchi  
Universidade Federal de Sao Paulo: Universidade Federal de Sao Paulo

Melissa Furlaneto Lellis Leite  
Universidade Federal de Sao Paulo: Universidade Federal de Sao Paulo

Solange Amorim Nogueira  
Hospital Israelita Albert Einstein

Jairo Wagner  
Hospital Israelita Albert Einstein

Mario Luiz Vieira Castiglioni  
Universidade Federal de Sao Paulo: Universidade Federal de Sao Paulo

Ming Chi Shih  
Universidade Federal de Sao Paulo

Rodrigo Affonseca Bressan (rodrigoabressan@gmail.com)  
Universidade Federal de Sao Paulo

Original research
Abstract

**Purpose:** The presynaptic dopamine transporter (DAT) modulates the uptake of dopamine by regulating its concentration in the central nervous system. We aimed to evaluate the DAT binding potential (DAT-BP) in a sample of healthy Brazilians through $[^{99m}Tc]$ TRODAT-1 single-photon emission computed tomography imaging.

**Methods:** We selected 126 healthy individuals comprising 72 men and 54 women, aged 18-80 years. We conducted semi-quantitative evaluation in transaxial slices, following which we identified the regions of interest in the striatal region using the occipital lobe as a region of non-specific DAT-BP. We found a decrease in DAT-BP in healthy individuals aged over 30 years, culminating in a 42% mean reduction after 80 years.

**Results:** There was no difference in the decrease by age group between the right ($R^2_{\text{linear}}=0.466$) and left striatum ($R^2_{\text{linear}}=0.510$). Women presented a higher DAT-BP than men (women: $R^2_{\text{linear}}=0.431$; men: $R^2_{\text{linear}}=0.457$); nonetheless, their decrease by age group was equal to that in men.

**Conclusion:** Our study sheds light on important DAT-BP findings in healthy Brazilian subjects. Our results will facilitate understanding of brain illnesses that involve the dopamine system, such as neuropsychiatric disorders.

2. Introduction

The presynaptic dopamine transporter (DAT) is involved in regulating synaptic dopamine levels by a reuptake mechanism [1, 2]. The striatum is a rich in dopamine. Thus, it has a high density of presynaptic DAT [3]. Findings from post-mortem examinations report on a reduction in the density of DAT in the striatum of patients with Parkinson’s (PD) and Alzheimer’s disease. Thus, measurement of the decrease in DAT may be an indicator of the loss of dopaminergic neurons [4, 5].

Several ligands for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging have displayed a high binding affinity and excellent imaging characteristics for DAT [6]. These imaging techniques require cyclotron produced radionuclides, such as $[^{11}C]$, $[^{18}F]$, and $[^{123}I]$, which limits their availability and use in routine clinical diagnosis [7]. Furthermore, $[^{99m}Tc]$ radiopharmaceuticals are used for nuclear medicine procedures. Current diagnostic medical imaging instruments are optimised for the gamma emission of $[^{99m}Tc]$. Therefore, a $[^{99m}Tc]$ tracer for in vivo binding with DAT would be ideal for a routine clinical study in humans [8, 9].

The TRODAT-1 is a tropane derivative labelled with $[^{99m}Tc]$ ($[^{99m}Tc]$ TRODAT-1). It crosses the blood brain barrier and has a high affinity for DAT [10–12]. SPECT scintigraphy with $[^{99m}Tc]$ TRODAT-1 can generate images of specific sites of DAT. $[^{99m}Tc]$ TRODAT-1 shows similar binding and imaging efficiency at much lower costs compared to other tracers, thus being more advantageous [9].
[99mTc] TRODAT-1 is being used in Brazil to investigate dopaminergic neurotransmission in PD [13–18]. However, there is lack of literature on the evaluation of DAT in healthy Brazilians for better understanding of dopaminergic neurodegeneration. Thus, we aimed to evaluate DAT density in a sample of healthy Brazilians using the [99mTc] TRODAT-1 SPECT image analysis.

3. Methods

Sample

We selected images from the [99mTc] TRODAT-1 image database of the Laboratory of Integrative Neuroscience (LiNC-EPM/UNIFESP). This database contains images of normal volunteers acquired from 2006 to 2014. The inclusion criteria were as follows: 1) no neurological disease, 2) no severe intellectual disability, 3) no comorbidity with Axis I disorders according to Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV), and 4) no artefacts in the images. Our study was approved by the Research Ethics Committee of the Universidade Federal de São Paulo (UNIFESP) (protocol number 0315/2017). The informed consent was obtained from each subject at the time of enrollment for imaging data.

Image Acquisition

We acquired all images on a double-headed gamma camera equipped with ultra-high-resolution fan beam collimators (General Electric Healthcare – GE Discovery and GE Hawkeye Infinia). We began emission scans 4 h after the intravenous injection of 814–888 MBq/2 mL [99mTc] TRODAT-1. The Institute of Nuclear Energy Research (Taiwan, China) produced the TRODAT-1 kits. Following their labelling according to a previously described methodology [19, 20], we extensively validated them [15, 17]. The acquisitions were made with a matrix of 128 × 128 × 16 on a circular orbit with 128 steps and 3600 rotations, 30 seconds by projection, with a zoom factor of 1.45. We used a sinogram to control the quality of the exam, thus revealing possible subject movements during the acquisition.

Image Analysis

The Xeleris GE software facilitated qualitative and semi-quantitative image analysis. We reconstructed the SPECT images with 8 mm thickness in transaxial, coronal, and sagittal slices by the Filtered Back Projection method. Moreover, we used a Chang attenuation correction and a Butterworth filter with a 0.45 cut off and order 10.

We evaluated the images through visual inspection and quantitative evaluation of the regions of interest (ROI). We defined the striatal ROIs slightly smaller than the actual structure to avoid partial volume effects. They were drawn on three consecutive transaxial slices that enabled better visualisation of the striatal DAT binding. We used their average to estimate the striatal concentration of DAT on the right and left sides of the brain. Thus, the ROIs were manually drawn at the striatal region with 150–155 pixel region with a specific binding of [99mTc] TRODAT-1 (high DAT concentration) and an elliptical drawn in
the occipital lobe area with a 400 pixel region of non-specific binding of [99mTc] TRODAT-1 (low DAT concentration) (Fig. 1). We calculated the BP using the formula:

$$BP = \frac{[STR - OCC]}{OCC}$$

where, BP = Binding Potential; STR = Striatal Region, specific binding region of [\textsuperscript{99m}Tc] TRODAT-1 to DAT; and OCC = Occipital Lobe, non-specific binding region of [\textsuperscript{99m}Tc] TRODAT-1 to DAT. Other modelling methods have validated the aforementioned method [21]. Two investigators independently analysed the images. They were blinded to the group conditions. However, they had been previously trained and achieved high inter-rater reliability (> 0.95) with an experienced rater in the group. The rater measured the striatal DAT binding for each subject at two different times and achieved an intra-rater reliability of > 0.95. This certified the test–retest reliability of our measurements.

**Statistical Analysis**

We used the SPSS v. 22.0 (IBM, NY, USA) for statistical analyses. We performed a simple percentage analysis to evaluate the DAT density over age. In addition, we conducted a linear regression to determine correlations between DAT density and sex or age. A p value of 0.05 was considered statistically significant.

**4. Results**

We selected 126 images from 126 healthy subjects comprising 72 (57.1%) men and 54 (42.9%) women, aged 18–80 years (mean age 46.17 + 15.43 years) (Table 1). The sample showed a normal distribution (K-S = 0.068; p = 0.200).
Table 1  
Sociodemographic characteristics of Brazilian healthy individuals

| Variable                      | N   | Mean    | S.D.   |
|-------------------------------|-----|---------|--------|
| Demographic                   | 126 |         |        |
| Age, years                    | 46,17 ± 15,43 |
| Years of education            | 14,07 ± 4,41 |
| Sex (M/F)                     | 72/54 |        |        |
| Dopamine Transporter density  |      |         |        |
| Total Striatum DAT-BP         | 3,25 ± 0,76 |
| Left Striatum DAT-BP          | 1,23 ± 0,48 |
| Right Striatum DAT-BP         | 1,13 ± 0,39 |

DAT-BP: dopamine transporter binding potential

We divided the sample by age group (6 groups, separated per decade) to evaluate the DAT density by age. Considering 18–30 years group the standard of DAT density, we performed a simple percentage analysis. We found that the DAT density can decrease by 42%, 56%, and 60% in the total striatum, right striatum, and left striatum, respectively in the last group (71–80 years) (Table 2; Graphs 1, 2, and 3).
Table 2
Percentage decrease of the binding potential (BP) of the DAT in striatum region in healthy individuals, divided by age group.

| Age Group    | Regions       | DAT-BP*  | Decrease in relation to 18–30 yo age group |
|--------------|---------------|----------|------------------------------------------|
| 18–30 years  | Total Striatum| 4.05 ± 0.46 |                                           |
|              | Right Striatum| 1.54 ± 0.24 |                                           |
|              | Left Striatum | 1.77 ± 0.33 |                                           |
| 31–40 years  | Total Striatum| 3.54 ± 0.58 | 13%                                      |
|              | Right Striatum| 1.27 ± 0.30 | 18%                                      |
|              | Left Striatum | 1.42 ± 0.37 | 20%                                      |
| 41–50 years  | Total Striatum| 3.29 ± 0.55 | 19%                                      |
|              | Right Striatum| 1.15 ± 0.30 | 25%                                      |
|              | Left Striatum | 1.23 ± 0.37 | 31%                                      |
| 51–60 years  | Total Striatum| 2.90 ± 0.66 | 28%                                      |
|              | Right Striatum| 0.95 ± 0.34 | 38%                                      |
|              | Left Striatum | 0.99 ± 0.35 | 44%                                      |
| 61–70 years  | Total Striatum| 2.61 ± 0.63 | 36%                                      |
|              | Right Striatum| 0.80 ± 0.31 | 48%                                      |
|              | Left Striatum | 0.81 ± 0.33 | 54%                                      |
| 71–80 years  | Total Striatum| 2.36 ± 0.13 | 42%                                      |
|              | Right Striatum| 0.68 ± 0.06 | 56%                                      |
|              | Left Striatum | 0.71 ± 0.15 | 60%                                      |

*Mean ± Std. Deviation

Findings from the linear regression analysis revealed a significant correlation between a decrease in the binding potential of DAT (DAT-BP) and an increasing age for all regions: total striatum $R^2 = 0.471 \ p < 0.001$ (Graph 4); right striatum $R^2 = 0.466 \ p < 0.001$; and left striatum $R^2 = 0.510 \ p < 0.001$ (Graph 5). Women showed a higher mean DAT-BP density than men. This was significantly correlated with a decreasing DAT and an increasing age (women $R^2 = 0.431 \ p < 0.001$ vs. men $R^2 = 0.457 \ p < 0.001$) (Graph 6).
5. Discussion

This is the first study to evaluate the DAT density in healthy Brazilians. Our results showed a decrease in the DAT density by age. Furthermore, they confirmed a persistent sex-related difference in DAT density in Brazilians.

DAT regulates the concentration of dopamine in the synaptic cleft through its reuptake into the presynaptic neurons. Moreover, it exerts an influence on dopamine function by modulating locomotor activity, cognition, and the reward system [22–26].

$[^{99m}Tc]TRODAT-1$ selectively binds to the dopamine transporters localised at the striatum. The binding potential of the DAT (DAT-BP) corresponds to the product of the free receptor density and affinity. Furthermore, it is calculated as the ratio of striatal specific binding to the concentration of steady-state, free, and unmetabolised plasma tracer [27, 28]. DAT ligands, such as $[^{99m}Tc]TRODAT-1$ are established markers for evaluating the changes in presynaptic DAT in vivo [6].

Previous studies reported on a decline in the striatal DAT at an approximate rate of 6–8% per decade in the human striatum [29–31], which is consistent with our results. Furthermore, we reported on a similarity in this decrease per decade in the right and left striatum. These findings corroborate the post-mortem reports of DAT loss with ageing [31]. Thus, in vivo methodologies may permit the evaluation of age-related degeneration of dopamine nerve terminals, in relation to the cognitive and motor deficits that occur in normal ageing. In addition, our results also corroborate with the literature on sex-related differences in DAT density [32–34]. It showed that the decrease in DAT per decade is similar in both sexes.

The use of DAT-SPECT facilitates the investigation of the presynaptic dopaminergic nigrostriatal pathway. Moreover, it is useful in clinical practice related to neurodegenerative diseases [35]. PD is characterised by the selective loss of dopamine neurons in the basal ganglia and substantia nigra. However, patients with PD manifest symptoms only when 50–80% of the nigrostriatal neurons are lost [36, 37].

Clinical diagnosis sometimes fails to identify at-risk individuals before a significant loss of dopamine neurons. The reduction of DAT binding in the prodromal stage of PD suggests an early synaptic dysfunction and the activation of compensatory changes to delay the onset of symptoms [35, 38]. Therefore, quantitative measurements of DAT binding at baseline could predict the emergence of late-disease motor fluctuations and dyskinesias [38].

Manual analysis of the images was a major limitation of our study. In addition, the images were not anatomically paired with computed tomography or magnetic resonance imaging for the ROIs. However, there were improvements in the pre- and post-processing (alignment, cut thickness, image reconstruction, attenuation corrections, and ROI delimitation). We failed to obtain data regarding ethnicity and laterality.
of the sample, which could be helpful in future studies. However, our sample contained 126 images of healthy individuals. Thus, a sample size strengthened our results.

6. Conclusion

DAT imaging is a good biomarker for evaluating the loss of dopaminergic neurons [39]. Moreover, our data support the safe application of [99mTc] TRODAT-1. The sex-associated differences and age-associated changes in DAT density can explain possible dopaminergic neuromodulation. Thus, these results may facilitate our understanding of brain illnesses involving the dopamine system, such as neuropsychiatric disorders, and their associated sex-related differences. Our study revealed important findings regarding DAT-BP values in healthy Brazilians. This in turn will enable the standardisation of DAT while investigating dopaminergic neurotransmission.

Declarations

ACKNOWLEDGEMENTS

We thank the Nuclear Medicine Department of Hospital Israelita Albert Einstein, São Paulo, Brazil, for their support in this work.

COMPLIANCE WITH ETHICAL STANDARDS

Funding: This study was funded by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil – Finance Code 001.

Conflict of Interest: Dr. Rodrigo Affonseca Bressan reports grants, personal fees, and nonfinancial support from Janssen, personal fees from Lundbeck, others from Roche, personal fees from Ache, and personal fees from Novartis, outside the submitted work. Marilia Alves dos Reis, Ary Gadelha, André C. Felício, Marcelo Queiroz Hoexter, Ilza Rosa Batista, Pedro Braga-Neto, Mariana Calzavara, Daniel Alves Cavagnolli, Cinthia Higuchi, Melissa Furlaneto Lellis Leite, Solange Amorim Nogueira, Jairo Wagner, Mario Luiz Vieira Castiglioni, and Ming Chi Shih declare no conflicts of interest inherent to this article.

Ethical approval: This study was approved by the ethics committee of the Universidade Federal de São Paulo (UNIFESP), protocol number 0315/2017. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent: Informed consent was obtained from all individual participants included in the study.

Availability of data and material: Not applicable.

Code availability: Not applicable.
Authors' contributions: All authors contributed to the study conception and design. Data collection it was made by Marilia Alves dos Reis, André C. Felício, Marcelo Queiroz Hoexter, Ilza Rosa Batista, Pedro Braganeto, Mariana Calzavara, Daniel Alves Cavagnolli, Cinthia Higuchi, Melissa Furlaneto Lellis Leite, Solange Amorim Nogueira, Jairo Wagner and Ming Chi Shih. Image analysis was performed by Marilia Alves dos Reis. Material preparation and statistical analysis were performed by Marilia Alves dos Reis, Ary Gadelha, Mario Luiz Vieira Castiglioni and Rodrigo Affonseca Bressan. The first draft of the manuscript was written by Marilia Alves dos Reis and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

References

1. Dresel SHJ, Kung MP, Plössl K, Meegalla SK, Kung HF. Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med. 1998;25:31–9.

2. Meegalla SK, Plössl K, Kung MP, Stevenson DA, Mu M, et al. Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents. J Med Chem. 1998;12(4):428–36.

3. Dresel SH, Kung MP, Huang XF, Plössl K, Hou C, et al. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons. J Nucl Med. 1999;40(4):660–6.

4. Agid Y. Parkinson's disease: pathophysiology. Lancet. 1991;337(8753):1321–4.

5. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology. 1993;43(12):6–16.

6. Shih MC, Hoexter MQ, Andrade LAF, Bressan RA. Parkinson's disease and dopamine transporter neuroimaging – a critical review. Sao Paulo Med J. 2006;124(3):168–75.

7. Fang P, Wu CY, Liu ZG, Wan WX, Wang TS, Chen SD. et. al. The Preclinical Pharmacologic Study of Dopamine Transporter Imaging Agent [99mTc]TRODAT-1. Nucl Med Biol. 2000;27:69–75.

8. Meegalla SK, Plössl K, Kung MP, Chumpradit S, Stevenson DA, et al. Synthesis and Characterization of Technetium-99m-Labeled Tropanes as Dopamine Transporter-Imaging Agents. J Med Chem. 1997;40(1):9–17.

9. Kung HF, Kung MP, Choi SR. Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med. 2003;33(1):2–13.

10. Kung MP, Stevenson DA, Plössl K, Meegalla SK, Beckwith A, et al. [99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24(4):372–80.

11. Meegalla SK, Plössl K, Kung MP, Stevenson DA, Mu M, et al. Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents.1998;12;41(4):428–36.

12. Kushner SA, McElgin WT, Kung MP, Mozley PD, Plössl K, et al. Kinetic Modeling of [99mTc]TRODAT-1: A Dopamine Transporter Imaging Agent. J Nucl Med. 1999;40:150–8.
13. Shih MC, Amaro E Jr, Ferraz HB, et al. Neuroimaging of the Dopamine Transporter in Parkinson’s Disease – First study using [99mTc]-TRODAT-1 and SPECT in Brazil. Arq Neuropsiquiatr. 2006;64(3-A):628–34.

14. Barsottini OGP, Felício AC, Aguiar PC, Godeiro-Junior C, Shih MC, et al. Clinical and molecular neuroimaging characteristics of Brazilian patients with Parkinson’s disease and mutations in PARK2 or PARK8 genes. Arq Neuropsiquiatr. 2009;67(1):7–11.

15. Shih MC, Andrade LAF, Amaro-Jr E, Felício AC, Ferraz HB, et al. Higher nigroestriatal dopamine neuron loss in early than late onset Parkinson’s disease? A [99mTc]-TRODAT-1 SPECT study”. Mov. Disord. 2007;(22):863–866.

16. Felício AC, Godeiro-Junior C, Moriyama TS, Shih MC. et. al. Degenerative parkinsonism in patients with psychogenic parkinsonism: A dopamine transporter imaging study”. Clin Neurol Neurosurg. 2010;112(4):282–5.

17. Felício AC, Moriyama TS, Godeiro-Junior C, Shih MC, Hoexter MQ, et al. Higher dopamine transporter density in Parkinson's disease patients with depression. Psychopharmacology. 2010;211(1):27–31.

18. Felício AC, Godeiro-Junior C, Shih MC, Borges V, Silva SM, et al. Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1. J Neurol Sci. 2010;291(1–2):64–8.

19. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plössl K, Lee HK. Imaging of dopamine transporters in humans with technetium99 m TRODAT-1. Eur J Nucl Med. 1996;23:1527–30.

20. Mozley PD, Stubbs JB, Plössl K, Dresel SH, Barraclough ED, et al. Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters. J Nucl Med. 1998;39:2069–76.

21. Acton PD, Meyer PT, Mozley PD, Plössl K, Kung HF. Simplified quantification of dopamine transporters in humans using [99mTc]TRODAT-1 and single-photon emission tomography. Eur J Nucl Med. 2000;27:1714–8.

22. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci. 1996;16(2):436–47.

23. Giros B, el Mestikawy S, Godinot N, et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol. 1992;42(3):383–90.

24. Donovan DM, Vandenbergh DJ, Perry MP, et al. Human and mouse dopamine transporter genes: conservation of 5'-fl anking sequence elements and gene structures. Brain Res Mol Brain Res. 1995;30(2):327–35.

25. Vandenbergh DJ, Persico AM, Hawkins AL, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 1992;14(4):1104–6.

26. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci. 1995;15(3 Pt 1):1714–23.
27. Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M. Low dopamine D2 receptor binding potential in social phobia. Am J Psychiatry. 2000;157(3):457–9.

28. Abi-Dargham A, Gandelman MS, DeErasquín GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996;37(7):1129–33.

29. Ma SY, Ciliax BJ, Stebbins G, et al. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol. 1999;409(1):25–37.

30. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol. 1989;26(4):551–7.

31. Van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J Nucl Med. 1995;36(7):1175–81.

32. Yamamoto H, Arimura S, Nakanishi A, et al. Age-related effects and gender differences in Japanese healthy controls for [123I]FP-CIT SPECT. Ann Nucl Med. 2017;31:407–12.

33. Mozley HL, Gur RC, Mozley PD, Gur RE. Striatal Dopamine Transporters and Cognitive Functioning in Healthy Men and Women. Am J Psychiatry. 2001;158:9.

34. Lee YH, Cha J, Chung SJ, Yoo HS, Sohn YH, Ye BS, et al. Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naive postmenopausal Parkinson's disease. Sci Rep. 2019;9(1):10531.

35. Palermo G, Ceravolo R. Molecular Imaging of the Dopamine Transporter. Cells. 2019;8:872.

36. Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain. 2004;127:1693–705.

37. Bressan RA, Shih MC, Hoexter MQ, Lacerda AL. Can molecular imaging techniques identify biomarkers for neuropsychiatric disorders? Rev Bras Psiquiatr. 2007;29:102–4.

38. Shih MC, Amaro E Jr, Ferraz HB, Hoexter MQ, Goulart FO, Wagner J, et al. Neuroimaging of the dopamine transporter in Parkinson's disease: first study using [99mTc]TRODAT-1 and SPECT in Brazil. Arq Neuropsiquiatr. 2006;64(3-A):628–34.

39. Mo SJ, Axelsson J, Jonasson L, Larsson A, Ögren MJ, et al. Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison. EJNMMI Res. 2018;8:100.